Pfizer

Related Content

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.
News | Hypertension
FDA Recalls Quinapril Hydrochloride and Hydrochlorothiazide Tablets by Pfizer

March 23, 2022 — MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer ...

Home March 23, 2022
arrow
Katherine Fornell, age 5, from suburban Chicago, receives her first dose of the COVID-19 vaccine during the first week it became available in the U.S. The FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine Oct. 29 for the prevention of COVID-19 in children 5 to 11 years of age. This was based on a safety review of more than 3,000 patients receiving the vaccine ages 5-11.
Feature | Coronavirus (COVID-19)
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Children Ages 5-11

November 5, 2021 — The U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID ...

Home November 05, 2021
arrow
The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec, 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance.  #COVID #COVID19 #SARSCoV2 #vaccine #COVIDVaccine
Feature | Coronavirus (COVID-19)| Dave Fornell, Editor
FDA Clears First COVID-19 Vaccine Under an Emergency Use Authorization

December 14, 2020 — The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for ...

Home December 14, 2020
arrow
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.
Technology | Heart Failure
FDA Clears New Treatments for Cardiomyopathy Caused by Transthyretin Mediated Amyloidosis

May 6, 2019 — The U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis ...

Home May 06, 2019
arrow
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study

April 6, 2018 — Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its ...

Home April 06, 2018
arrow
News | Antiplatelet and Anticoagulation Therapies
BMS-Pfizer Alliance Releases Real-World Data on Oral Anticoagulants in Non-Valvular Atrial Fibrillation

November 16, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated ...

Home November 16, 2017
arrow
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin

August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data ...

Home August 28, 2017
arrow
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals
PCSK9 Inhibition With Bococizumab Yields Mixed Results

March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when ...

Home March 22, 2017
arrow
Pfizer Bristol-Myers Squibb Eliquis
News
FDA Receives Resubmission of the Apixaban Drug Application to Reduce Stroke in Patients With Atrial Fibrillation

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA ...

Home October 01, 2012
arrow
News
Pfizer Withdraws Sitaxentan After New Risks Found

December 13, 2010 – Based on emerging safety information, the pulmonary arterial hypertension (PAH) drug sitaxentan is ...

Home December 13, 2010
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now